Not provided
Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| UM1AI068632 | U.S. NIH Grant/Contract | View source | |
| UM1AI068616 | U.S. NIH Grant/Contract | View source | |
| UM1AI106716 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
IMPAACT P1107 will describe the outcomes of HIV-infected persons, ages 12 months and older, who undergo transplantation with CCR5Δ32 cord blood stem cells for treatment of cancer, hematopoietic disease, or other underlying disease.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Pre-Transplant Cohort | HIV-1 infected participants, enrolled prior to transplant, who receive a heterozygous or homozygous CCR∆32 cord blood transplant | ||
| Post-Transplant Cohort | HIV-1 infected participants, enrolled within 2 years after transplant, who receive a homozygous CCR∆32 cord blood transplant |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Survival | Survival and event-free survival at 100 days, Week 26, Week 52, and then every six months until five years post-transplant | Through 5 years post-transplant |
| Graft versus host disease | Graft versus host disease | Through 5 years post-transplant |
| Engraftment | Chimerism (≥ 98% of blood cells bearing CCR5∆32) and time to hematopoietic cell and immune recovery | Through 5 years post-transplant |
| HIV DNA level | HIV-1 proviral DNA levels in peripheral blood | Through 5 years post-transplant |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
• Received, or planning to receive, more than one CCR5Δ32 homozygous cord blood or bone marrow transplant.
Not provided
Not provided
Not provided
HIV-1 infected children and adults who undergo cord blood stem cell transplantation for treatment of cancer, hematopoietic disease, or other underlying disease
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yvonne Bryson, MD | University of California, Los Angeles | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Weill Cornell Uptown Clinical Research Site (7803) | New York | New York | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 36931242 | Derived | Hsu J, Van Besien K, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, Petz L, Moore TB, Chen YH, Pallikkuth S, Dhummakupt A, Cortado R, Golner A, Bone F, Baldo M, Riches M, Mellors JW, Tobin NH, Browning R, Persaud D, Bryson Y; International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT) P1107 Team. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023 Mar 16;186(6):1115-1126.e8. doi: 10.1016/j.cell.2023.02.030. |
| Label | URL |
|---|---|
| Study website | View source |
Not provided
Individual participant data that underlie results in the publication, after deidentification.
Beginning 3 months following publication and available throughout period of funding of the International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Network by NIH.
With whom? Researchers who provide a methodologically sound proposal for use of the data that is approved by the IMPAACT Network.
For what types of analyses? To achieve aims in the proposal approved by the IMPAACT Network.
By what mechanism will data be made available? Researchers may submit a request for access to data using the IMPAACT "Data Request" form at: https://www.impaactnetwork.org/resources/study-proposals.htm. Researchers of approved proposals will need to sign an IMPAACT Data Use Agreement before receiving the data.
Not provided
Not provided
| ID | Term |
|---|---|
| D015658 | HIV Infections |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D015229 | Sexually Transmitted Diseases, Viral |
Not provided
Not provided
Not provided
Not provided
Not provided
For consenting participants, blood and tissue samples
| D012749 | Sexually Transmitted Diseases |
| D016180 | Lentivirus Infections |
| D012192 | Retroviridae Infections |
| D012327 | RNA Virus Infections |
| D014777 | Virus Diseases |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D007153 | Immunologic Deficiency Syndromes |
| D007154 | Immune System Diseases |